OND-1: The Truth About the 1990 Cyclosporine Hair Trial
Published by AmpleLab Research
Cyclosporine's history as a hair loss candidate goes back further than most pipeline compounds we cover, all the way to a small human trial in 1990, and it tends to get described in more dramatic terms than the original data support: a proven cure, abandoned for reasons that were never quite about the science. Before writing anything else in this article, we went back to the 1990 paper itself rather than relying on how it tends to get summarised. What the paper reported matters a great deal for understanding why this line of research stalled, and for judging the modern attempt to revive it.
The underlying science, though, is real, and it did not stay stuck in 1990. A 2018 mechanistic study identified a molecular pathway through which cyclosporine can promote hair growth, and a South Korean company, Orient Bio, has spent over a decade trying to turn a cyclosporine-derived compound called OND-1 into an approvable hair loss drug. This article covers all three threads: what the 1990 trial showed, what the science says now, and where OND-1 stands today.
The 1990 Trial, Read in Full
Cyclosporine A is a systemic immunosuppressant, used since the 1980s to prevent organ transplant rejection, with a well-documented side effect of excessive hair growth (hypertrichosis). Researchers at the Technion-Israel Institute of Technology in Haifa, who had previously shown cyclosporine could stimulate hair growth in human scalp skin grafted onto nude mice, ran a small double-blind trial to see whether a topical formulation could do the same thing on an actual balding human scalp.
Over 4 months, 13 men with male pattern alopecia were split unevenly: 10 received topical cyclosporine, 3 received an olive oil vehicle. Five participants did not complete the study, leaving 8 evaluable. Hair growth was assessed by photographs and hair counts. A marked increase in hair growth was reported in 2 of the 8 completers, and in only one of those two was the growth described as cosmetically satisfactory. No systemic or cutaneous side effects were reported during the four-month study.
That is the entire reported result: a modest, mixed signal in a small sample, not a clear success story. A later academic review of cyclosporine and hair growth, published independently of this trial, summarised it plainly: topical cyclosporine for male pattern alopecia "has not been successful." That is a fair, if blunt, characterisation of a study where six of the eight evaluable participants did not show a marked increase in hair growth, and the unequal 10-to-3 group sizes make it a weak basis for strong conclusions either way.
Why the Trial Went Nowhere
A modest result in 8 people, with an unbalanced control group, is hardly the sort of evidence that would require a conspiracy to explain why development did not continue. A 2-of-8 result from such a small, unevenly allocated study is weak evidence either way.
The more mundane, and better-supported, explanation for why cyclosporine never became a practical hair loss drug is its toxicity, compounded by the weak clinical evidence. Systemic cyclosporine carries real risks, including kidney toxicity, high blood pressure, and increased infection risk from immunosuppression, an acceptable trade-off for a transplant patient facing organ rejection, and an unacceptable one for a cosmetic condition like pattern hair loss. Even a topical formulation raises the question of how much systemic absorption occurs, a question this 1990 trial did not resolve for its two responders. Later academic authors studying the same drug were explicit about this trade-off: cyclosporine "can potently induce hair growth in humans," but "it cannot be effectively used to restore hair growth because of its toxic profile."
What Modern Research Found
The scientifically interesting follow-up did not try to repeat the 1990 trial. Instead, a 2018 study used cyclosporine as a research tool rather than a candidate drug, treating human scalp hair follicles with it in organ culture to find out which of its many biological effects was actually responsible for the hair growth signal, so that effect could potentially be reproduced without the immunosuppression attached. Using microarray analysis, the researchers found cyclosporine significantly reduced a Wnt-signalling inhibitor called SFRP1 in the dermal papilla, the structure at the base of the follicle that helps regulate the hair growth cycle. Reducing SFRP1 therefore removes some of the suppression on Wnt/β-catenin signalling, a pathway strongly linked to keeping follicles in the active growth (anagen) phase.
Using cyclosporine A as a research tool on human scalp hair follicles ex vivo, the authors identified SFRP1, a secreted Wnt inhibitor, as significantly downregulated by cyclosporine in the dermal papilla. Pharmacological experiments confirmed SFRP1 regulates canonical Wnt/β-catenin activity in the human hair bulb. Rather than pursuing cyclosporine itself, the team tested WAY-316606, a separate, reportedly well-tolerated SFRP1 antagonist, and found it enhanced human hair shaft production and keratin expression, and inhibited follicle regression, in the same ex vivo model, without using cyclosporine or its immunosuppressive effects at all.
Two details make this paper worth knowing about beyond its findings. First, one of its co-authors is Amos Gilhar, the same researcher behind the original 1990 trial, returning to the same drug nearly three decades later with better tools. Second, this is peer-reviewed academic work that was not conducted as an OND-1 company study, which makes it an important mechanistic anchor for this area, independent of the OND-1 programme itself. That does not establish that OND-1 produces its effects through SFRP1 specifically; Orient Bio describes Wnt pathway involvement in general terms rather than identifying a single confirmed molecular mechanism for its own compound.
OND-1: Orient Bio's Long-Running Attempt
OND-1 is a cyclosporine A derivative originally developed by the Korean consumer goods and cosmetics group LG Household & Health Care, later licensed to Orient Bio, a KOSPI-listed South Korean company. The pitch, per Orient Bio's own public statements, is the same one implied by the 2018 mechanistic work above: reduce the immune-suppressing action while keeping the hair-growth-promoting one. Unlike DLQ01, OND-1's identity as a cyclosporine derivative is not speculation; Orient Bio states it directly.
According to Orient Bio's own regulatory filings, OND-1 received FDA Investigational New Drug clearance in 2011 and Korean Ministry of Food and Drug Safety approval to proceed in 2015, with a Phase 1 trial conducted at a national university hospital in Korea completing in January 2017. From the second half of 2019, the company describes moving into preclinical work aimed at Phase 2. Critically, none of the company's public filings AmpleLab reviewed report actual efficacy or hair-count numbers from that completed 2017 Phase 1 trial, only that it finished successfully. For a trial that concluded more than eight years ago, that is a significant gap in the public record.
What happened next explains the long gap since. The original 2017 trial tested a topical (transdermal) formulation, and Korean financial press reporting from late 2024 indicates that formulation delivered less drug beneath the scalp than the company had hoped. Rather than continue with topical dosing, Orient Bio shifted OND-1 toward a sustained-release injectable formulation using PLGA (poly-lactic-co-glycolic acid), a biodegradable polymer used elsewhere in medicine for slow drug release. That meant restarting patent filings and preclinical toxicology largely from scratch: a Korean patent for the PLGA-based delivery system was registered in November 2022, a corresponding Japanese patent was granted in January 2026, and primate toxicology work, a standard preclinical requirement before human dosing, began under contract in January 2025 and was reported as still ongoing in the company's most recent filing. In other words, the OND-1 that eventually enters another human trial is likely to be a materially different formulation from the one tested in the completed 2017 Phase 1 study, which is worth keeping in mind given how far apart those two trials sit in time.
Through 2026, Orient Bio has issued a steady stream of press releases about OND-1, including an announcement in July that it would target the female pattern hair loss market specifically, citing OND-1's non-hormonal mechanism. Some of this coverage, particularly an August 2026 report picked up by international aggregator sites, described preclinical data showing OND-1 as up to 10 times more potent than topical minoxidil. AmpleLab traced this comparison back to the company's own regulatory filings, which state that OND-1 produced greater hair growth than Pfizer's Rogaine (5% minoxidil) in an experiment using macaques with naturally occurring scalp hair loss.
Orient Bio describes this as a particularly relevant animal model for human scalp biology. Separate human hair follicle culture experiments reported in the same filings also found a hair-growth-promoting effect, although without a comparable numerical figure. That gives the "10x" claim a real preclinical basis, but it remains an animal-model comparison, not a human clinical result, and readers should not treat a "10x minoxidil" headline as evidence of what OND-1 would do in a person.
Who Orient Bio Actually Is
Orient Bio's core, revenue-generating business is not pharmaceutical drug development. Founded in 1959, the company's primary operations are producing laboratory animals and biomaterials (rodents, rabbits, primates, and SPF eggs used in vaccine production) and providing contract research organisation (CRO) and preclinical research services, with a technology partnership with the US firm Charles River. OND-1 sits alongside a humanised-mouse programme and an AI-driven biological data platform as one of three stated growth pillars the company has recently been promoting, on top of that core animal-supply business. This does not make OND-1 illegitimate, Orient Bio's laboratory-animal and toxicology infrastructure is directly relevant to running the preclinical work OND-1 currently needs, but it is worth knowing that the company behind the headlines is not a dedicated, single-asset drug developer.
It is also worth knowing that Orient Bio's stock has drawn regulatory attention connected to OND-1 news before. In late 2024, the Korea Exchange queried the company after a sharp share-price spike, and Orient Bio's response cited its new drug development plans, OND-1 among them. The company also carried out a capital restructuring in 2026. None of this says anything about whether OND-1 works, but it is useful context when weighing promotional coverage timed around development announcements.
Common Questions
Did a 1990 cyclosporine trial really prove hair could be regrown?
Not convincingly. The actual 1990 trial (Gilhar et al., JAAD) found a marked increase in hair growth in only 2 of 8 evaluable patients, with just one showing cosmetically noticeable results, in a small, unevenly allocated study. That is a weak, mixed result, not the dramatic breakthrough sometimes described online.
Why was topical cyclosporine abandoned as a hair loss treatment?
The available evidence points to a weak clinical result, while cyclosporine's toxicity makes the drug itself an unattractive long-term treatment for a cosmetic condition. There is no credible evidence that a clinically effective hair-loss treatment was suppressed.
What is OND-1?
OND-1 is a cyclosporine A derivative for hair loss, originally developed by LG Household & Health Care and now under development by Orient Bio, a Korean company. It has held FDA IND clearance since 2011 and completed a Korean Phase 1 trial in 2017, but the company is now reformulating it as a sustained-release injectable rather than the original topical form, and has not publicly released the 2017 trial's efficacy data.
Is OND-1 available or close to approval?
No. OND-1's reformulated injectable version is still in preclinical toxicology testing as of the company's most recent public filing, with no publicly confirmed date for entering a new Phase 1 or 2 trial in its current form. It is not approved anywhere and is not available to buy.
Selected Research
This article is provided for educational purposes and does not constitute medical or investment advice. OND-1 is an investigational compound not approved for any use by the FDA, MHRA, Korean MFDS, or any other regulatory body. Systemic cyclosporine is a prescription immunosuppressant with serious risks and is not a hair loss treatment. AmpleLab products are unrelated to cyclosporine or OND-1 and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.